Company / Total Debt
Gain Therapeutics, Inc. Total Debt History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$328.3K
FY2024
5-year range
$328.3K / $590.5K
FY2021-FY2024
Trend
-26.9%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Debt has declined for 3 consecutive years, from $590,468 in FY2021 to $328,327 in FY2024.
Based on SEC 10-K filings.
$328,327 in FY2024 with a 3-year CAGR of -17.8%.
Improved from $495,258 to $328,327 over the past 2 years.
Total Debt over time
Growth rates
- 3-Year CAGR
- -17.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Gain Therapeutics, Inc.'s total debt has declined for 3 consecutive years.
- 3-year CAGR of -17.8%, indicating a declining trend.
- In FY2024, total debt decreased 26.9% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $328.3K | -26.9% |
| FY2023 | $449.1K | -9.3% |
| FY2022 | $495.3K | -16.1% |
| FY2021 | $590.5K | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026